{"task_id": "9248f2ca3133e1cb", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 188/464)", "text": " IPI prognostic factors\n176\nNon-Hodgkin\u2019s Lymphoma\n\n--- Page 198 ---\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nCLINICAL FEATURES\njaw pain and numbness, radi\ncular pain, back pain, neck pain/rigidity, confusion,\ncranial nerve deficits (especially II, III, V, VI, VII),\nfocal weakness, sensory changes, headaches\n\u0002\nDIAGNOSIS\nlumbar puncture with positive cytol\nogy (sens 60% with single attempt, 3 attempts for\nincreased yield), gadolinium enhanced MRI show\ning enhancement and enlargement of one or more\ncranial nerves due to tumor infiltration\n\u0002\nTREATMENTS\nhigh dose steroid (dexamethasone\n12 20 mg PO/IV daily), radiation to the site of\ndisease, intrathecal methotrexate, or cytarabine.\nImportant to treat underlying systemic disease.\nHighly selected patients may benefit from high\ndose chemotherapy with stem cell transplantation\nwith better outcomes. Median survival after CNS\nrecurrence is 3 months\nLOCALIZED PARANASAL SINUS LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\nusually\nDLBCL\ntype.\nMay\ninvolve CNS if invade through the base of skull\n\u0002\nCLINICAL FEATURES\nlocal pain, rhinorrhea, nasal or\nupper airway obstruction, facial swelling, epistaxis,\ndiplopia, visual loss\n\u0002\nTREATMENTS\nCHOPR\u00033 + involved field radiation\n+ intrathecal chemotherapy\u00036\nMUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)\n\u0002\nPATHOPHYSIOLOGY\nextranodal marginal zone B\ncell lymphomas that present with localized disease\ninvolving the GI tract, salivary glands, thyroid,\norbit, conjunctiva, breast, and lung. Note that dif\nfuse large cell lymphoma and mantle cell lym\nphoma also commonly involve GI mucosa\n\u0002\nASSOCIATIONS\nH. pylori associated chronic gastri\ntis, celiac disease, crohn\u2019s disease, gastrointestinal\nnodular lymphoid hyperplasia\n\u0002\nDIAGNOSIS\nfor gastric MALT, need to determine\npresence of H. pylori by biopsy (gastroscopy) \u0004\nurea breath test\n\u0002\nTREATMENTS\nfor H. pylori positive gastric MALT,\ntriple therapy may be adequate. Need to confirm\neradication of H. pylori. Follow closely with gastro\nscopy. If MALT persists for over 8 12 months,\nshould\nconsider\nsingle agent\nchemotherapy\n(cyclophosphamide, chlorambucil) or involved\nfield radiation. Partial gastrectomy may be needed\nfor hemorrhage or perforation\nACUTE LYMPHOBLASTIC LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\ncontinuum\nof\npresentation\nwith acute lymphoblastic leukemia. Considered\nlymphoma if < 5% blasts in bone marrow; other\nwise, considered leukemia\n\u0002\nCLINICAL FEATURES\nusually mediastinal mass in\nyoung males\nSPECIFIC ENTITIES (CONT\u2019D)\nBURKITT\u2019S LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\nt(8;14)\nleading\nto\nc myc\noverexpression\n\u0002\nCLINICAL\nFEATURES\nusually\nadvanced\nstage\n(80 90%). Abdominal mass, CNS, breast/ovarian\ninvolvement, and nodal sites but mediastinum\nusually spared\nTESTICULAR LYMPHOMA\n\u0002\nPATHOPHYSIOLOGY\n60% primary testicular lym\nphoma, 40% spread from other sites. Frequently\nDLBCL or immunoblastic subtype\n\u0002\nCLINICAL\nFEATURES\npainless testicular mass in\nolder man. High risk for recurrence, particularly\nCNS relapse\n\u0002\nDIAGNOSIS\nscrotal U/S\n\u0002\nTREATMENTS\nunilateral orchiectomy + CHOPR +\ninvolved field radiation to scrotum + intrathecal\nchemotherapy if stage III/IV disease\nPOST TRANSPLANT LYMPHOPROLIFERATIVE\nDISORDERS (PTLD)\n\u0002\nPATHOPHYSIOLOGY\nmostly of host origin and\nusually EBV positive (LMP 1 oncogene). EBV nega\ntive PTLD present later and are more aggressive\nthan EBV positive PTLD. Mostly B cell non Hodg\nkin\u2019s lymphoma and very rarely T cell or NK cell\nlymphomas\n\u0002\nRISK FACTORS\nhigh degree of immunosuppres\nsion, pre transplant EBV negativity. Risk highest\nin the first year, then reduces by 80%\n\u0002\nCLINICAL\nFEATURES\nclinical\nspectrum\nincludes\nreactive plasmacytic hyperplasia (55%, infectious\nmononucleosis like illness with no malignant trans\nformation), polymorphic B cell hyperplasia (30%,\npolyclonal cytogenetic abnormalities, immunoglo\nbulin gene rearrangements, and disruption of\nunderlying tissue architecture), and B or T cell\nlymphomas (15%, monoclonal malignancy)\n\u0002\nTREATMENTS\nreduction\nin\nimmunosuppression\n(may be sufficient for hyperplasia without mono\nclonal\ncomponent),\nrituximab,\nchemotherapy\n(CHOP), antiviral agents, IVIG, surgical resection,\nradiation, interferon a. Overall survival 25 35%.\nPrognostic factors include advanced age, perfor\nmance status >1, involved site >1\nMYCOSIS FUNGOIDES\n\u0002\nPATHOPHYSIOLOGY\nindolent cutaneous T cell lym\nphoma. Stages include premycotic, plaque, and\ntumor stage. Sezary syndrome is a variant of myco\nsis fungoides with a triad of erythroderma, lym\nphadenopathy, and leukemia\n\u0002\nCLINICAL FEATURES\nlocalized patches or plaques\nevolving into nodules and diffuse exfoliative ery\nthroderma associated with abnormal circulating\ncells. Poor prognostic factors include extensive\nNon-Hodgkin\u2019s Lymphoma\n177", "text_length": 4657, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 188/464)", "type": "chunk", "chunk_index": 187, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.504251", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.505053", "status": "complete", "chunks_added": 3}